Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biotherapeutics

Steffen Goletz's Biography



Steffen Goletz, Chief Executive & Scientific Officer, Glycotope GmbH

Dr. Steffen Goletz, CEO, CSO and co-founder of the biotech company GLYCOTOPE, studied biology, biochemistry and molecular biology at the universities in Heidelberg, Kaiserslautern, Manchester (UK) and Berlin and holds a Ph.D. in biochemistry. During his scientific career he worked for renowned research institutions including the Max Delbrueck Centre for Molecular Medicine (Berlin), the MRC Centre for Protein Engineering (Cambridge, UK), and the German Cancer Research Centre in Heidelberg. During his research, Dr. Goletz has focused on glycobiology, tumor immunology, antibody engineering and cellular engineering. As CSO, Steffen is responsible for the extremely successful development of GLYCOTOPEs product pipeline of glycooptimized biotherapeutics with 4 products currently in clinical trials. GLYCOTOPE developed the novel expression platform GlycoExpress based on human glycoengineered cell lines which is used for the generation of improved biopharmaceuticals with fully human and optimized glycosylation.

Steffen Goletz Image

Glycooptimized Biotherapeutics by Production in GlycoExpress™

Thursday, 28 June 2012 at 11:15

Add to Calendar ▼2012-06-28 11:15:002012-06-28 12:15:00Europe/LondonGlycooptimized Biotherapeutics by Production in GlycoExpress™SELECTBIOenquiries@selectbiosciences.com

GlycoExpressTM is a toolbox of glycoengineered human cell lines for high yield production of fully human glycosylated biotherapeutics. These are glycooptimized in respect to bioactivity, bioavailability, immunogenicity and patient coverage obtaining manifold improved Biobetters.


Add to Calendar ▼2012-06-27 00:00:002012-06-28 00:00:00Europe/LondonBiotherapeuticsSELECTBIOenquiries@selectbiosciences.com